| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FOXC1 |
| Uniprot No | Q12948 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-553aa |
| 氨基酸序列 | MQARYSVSSPNSLGVVPYLGGEQSYYRAAAAAAGGGYTAMPAPMSVYSHPAHAEQYPGGMARAYGPYTPQPQPKDMVKPPYSYIALITMAIQNAPDKKITLNGIYQFIMDRFPFYRDNKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYWTLDPDSYNMFENGSFLRRRRRFKKKDAVKDKEEKDRLHLKEPPPPGRQPPPAPPEQADGNAPGPQPPPVRIQDIKTENGTCPSPPQPLSPAAALGSGSAAAVPKIESPDSSSSSLSSGSSPPGSLPSARPLSLDGADSAPPPPAPSAPPPHHSQGFSVDNIMTSLRGSPQSAAAELSSGLLASAAASSRAGIAPPLALGAYSPGQSSLYSSPCSQTSSAGSSGGGGGGAGAAGGAGGAGTYHCNLQAMSLYAAGERGGHLQGAPGGAGGSAVDDPLPDYSLPPVTSSSSSSLSHGGGGGGGGGGQEAGHHPAAHQGRLTSWYLNQAGGDLGHLASAAAAAAAAGYPGQQQNFHSVREMFESQRIGLNNSPVNGNSSCQMAFPSSQSLYRTSGAFVYDCSKF |
| 预测分子量 | 62.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FOXC1重组蛋白的模拟参考文献示例(内容为虚构，仅作格式参考)：
---
1. **"Purification and functional analysis of recombinant FOXC1 transcription factor"**
*Smith A, et al. (2018)*
摘要：本研究描述了FOXC1重组蛋白在大肠杆菌中的高效表达与纯化方法，并验证其体外结合特定DNA序列的能力，为后续转录调控机制研究提供工具。
2. **"FOXC1 recombinant protein rescues cellular migration defects in corneal dystrophy models"**
*Lee J, et al. (2020)*
摘要：通过体外递送FOXC1重组蛋白至角膜细胞，恢复了因FOXC1突变导致的细胞迁移功能障碍，提示其在遗传性角膜疾病治疗中的潜在应用。
3. **"Structural insights into FOXC1-DNA interaction via crystallography of recombinant protein complexes"**
*Zhang Y, et al. (2021)*
摘要：解析了FOXC1重组蛋白与靶DNA的复合物晶体结构，揭示了关键氨基酸残基在识别DNA基序中的作用，为突变致病机制提供结构生物学依据。
4. **"Recombinant FOXC1 inhibits epithelial-mesenchymal transition in breast cancer cells"**
*Chen R, et al. (2019)*
摘要：证明外源性FOXC1重组蛋白可下调TGF-β信号通路，抑制乳腺癌细胞EMT进程，提示其作为肿瘤转移干预策略的可行性。
---
注：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索具体文献。
FOXC1. a member of the forkhead box (FOX) transcription factor family, plays critical roles in embryonic development, particularly in the formation of the anterior eye segment, cardiovascular system, and neural crest-derived tissues. It regulates gene expression by binding to DNA through its conserved forkhead domain, influencing cellular processes like proliferation, differentiation, and migration. Mutations in FOXC1 are linked to congenital disorders such as Axenfeld-Rieger syndrome, glaucoma, and heart defects, highlighting its biological and clinical significance.
Recombinant FOXC1 protein is engineered using genetic cloning techniques, where the FOXC1 gene is expressed in host systems (e.g., E. coli or mammalian cells) to produce purified, functional protein. This recombinant form retains the DNA-binding and regulatory properties of native FOXC1. enabling researchers to study its molecular interactions, signaling pathways, and downstream targets in controlled settings. It is often tagged (e.g., His-tag) for ease of purification and detection.
In research, recombinant FOXC1 serves as a tool to investigate disease mechanisms, particularly in developmental anomalies and ocular pathologies. For example, studies use it to analyze how FOXC1 dysfunction disrupts tissue morphogenesis or contributes to glaucoma pathogenesis. It also aids in screening potential therapeutic compounds targeting FOXC1-related pathways. Additionally, the protein is utilized in structural studies to map functional domains or mutation effects, providing insights into genotype-phenotype correlations.
Beyond basic research, recombinant FOXC1 holds potential in gene therapy and regenerative medicine, such as restoring normal function in cells with FOXC1 deficiencies. However, challenges remain in optimizing delivery methods and ensuring specificity in clinical applications. Overall, recombinant FOXC1 is a vital resource for unraveling the protein’s role in health and disease, bridging molecular biology with translational medicine.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
